Peng He

944 total citations
42 papers, 658 citations indexed

About

Peng He is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peng He has authored 42 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peng He's work include Cytokine Signaling Pathways and Interactions (5 papers), Fluid Dynamics and Turbulent Flows (4 papers) and HER2/EGFR in Cancer Research (4 papers). Peng He is often cited by papers focused on Cytokine Signaling Pathways and Interactions (5 papers), Fluid Dynamics and Turbulent Flows (4 papers) and HER2/EGFR in Cancer Research (4 papers). Peng He collaborates with scholars based in China, United States and Japan. Peng He's co-authors include Huazhong Tang, Yihua Chen, Minoru Takemoto, Takahiro Ishikawa, Koutaro Yokote, Masaki Fujimoto, Mingyao Liu, Shunichiro Onishi, Zhengfang Yi and Yoshiro Maezawa and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Peng He

38 papers receiving 645 citations

Peers

Countries citing papers authored by Peng He

Since Specialization

Citations

This map shows the geographic impact of Peng He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peng He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peng He more than expected).

Fields of papers citing papers by Peng He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peng He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peng He. The network helps show where Peng He may publish in the future.

Co-authorship network of co-authors of Peng He

This figure shows the co-authorship network connecting the top 25 collaborators of Peng He. A scholar is included among the top collaborators of Peng He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peng He. Peng He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or younger 2025 ·npj Genomic Medicine ·Jing Li, Lili Chen, Xuhui Chen, (unknown), (unknown), Minyan Chen, (unknown), Yali Wang, (unknown), (unknown), Peng He, (unknown), Chuan Wang, Fangmeng Fu	0
2	Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis 2025 ·Journal of Medicinal Chemistry ·Peng He, (unknown), (unknown), Hang Yin	7
3	Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China 2024 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Peng He, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Wenhui Guo, Minyan Chen, (unknown), Chuan Wang, Fangmeng Fu	2
4	Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance 2023 ·Journal of Medicinal Chemistry ·Peng He, (unknown), (unknown), Yue Sun, (unknown), (unknown), (unknown), Xueli Zhang, Mingyao Liu, Xiufeng Pang, Yihua Chen	16
5	Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer 2023 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Wenjing Liu, Peng He, (unknown), Yuzhan Li, (unknown), Ai‐Qun Jia, Ceshi Chen, Yihua Chen	4
6	Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway 2023 ·Cancer Letters ·Yuzhu Zhang, Jing Chen, (unknown), Jun Ling, Huachao Li, Peng He, Ning Liu, Qianjun Chen, Yihua Chen, Luqi Huang	24
7	Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis 2023 ·Breast Cancer Research and Treatment ·Peng He, (unknown), Minyan Chen, Meng Huang, (unknown), (unknown), Yuxiang Lin, Chuan Wang, Fangmeng Fu	0
8	Non-Invasive Prediction of Survival Time of Midline Glioma Patients Using Machine Learning on Multiparametric MRI Radiomics Features 2022 ·Frontiers in Neurology ·(unknown), Yuting Liao, Jiangfen Zhou, (unknown), Peng He, Sheng‐Nan Wu, Wensheng Wang, Quan Zhou	6
9	Discovery of 1,5-diaryl-1,2,4-triazole Derivatives as Myoferlin Inhibitors and Their Antitumor Effects in Pancreatic Cancer 2022 ·Future Medicinal Chemistry ·(unknown), (unknown), Yunqi Li, Yuan He, (unknown), (unknown), Peng He, Zhengfang Yi, Yihua Chen	2
10	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide 2021 ·Clinical Cancer Research ·Johann S. de Bono, Mark T. Fleming, Judy S. Wang, Richard Cathomas, (unknown), John Bothos, Mary Jane Hinrichs, Qu Zhang, Peng He, Marna Williams, Anton I. Rosenbaum, Meina Liang, (unknown), Song Cho, Pablo Martínez, Daniel P. Petrylak	33
11	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer 2021 ·Molecular Cancer Therapeutics ·Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, (unknown), Mayukh Das, Manish R. Patel	73
12	Nanoparticles and photochemistry for native-like transmembrane protein footprinting 2021 ·Nature Communications ·Jie Sun, Xiaoran Roger Liu, Shuang Li, Peng He, Weikai Li, Michael L. Gross	22
13	Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth 2020 ·Journal of Medicinal Chemistry ·Weikai Guo, (unknown), Qiansen Zhang, (unknown), (unknown), (unknown), Peng He, (unknown), Shifen Xu, Xiufeng Pang, Mingyao Liu, Zhengfang Yi, Yihua Chen	25
14	Open conformation of tetraspanins shapes interaction partner networks on cell membranes 2020 ·The EMBO Journal ·Yihu Yang, Xiaoran Roger Liu, Zev J. Greenberg, Fengbo Zhou, Peng He, Lingling Fan, (unknown), Guomin Shen, Takeshi Egawa, Michael L. Gross, Laura G. Schuettpelz, Weikai Li	37
15	Glutamatergic lateral hypothalamus promotes defensive behaviors 2020 ·Neuropharmacology ·Li Chen, Ping Cai, Renfei Wang, (unknown), Huiyun Chen, (unknown), (unknown), (unknown), Jian Chen, (unknown), Peng He, Bingfeng Zhang, Jiyuan Liu, Wenxiang Wang, Huangyuan Li, Chang‐Xi Yu	14
16	Basal forebrain GABAergic neurons promote arousal and predatory hunting 2020 ·Neuropharmacology ·Ping Cai, Li Chen, (unknown), Jing Yao, Huiyun Chen, (unknown), (unknown), Peng He, (unknown), Jiyuan Liu, Jian Chen, (unknown), (unknown), (unknown), Guoqiang Chen, (unknown), (unknown), Huangyuan Li, Wenxiang Wang, Chang‐Xi Yu	11
17	Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy 2019 ·Current Topics in Medicinal Chemistry ·Peng He, Wenbo Zhou, Mingyao Liu, Yihua Chen	1
18	Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms 2016 ·Journal of Nephrology ·Peng He, Harukiyo Kawamura, Minoru Takemoto, Yoshiro Maezawa, Takahiro Ishikawa, Ryoichi Ishibashi, Kenichi Sakamoto, (unknown), Akiko Hattori, (unknown), Shintaro Ide, Kana Ide, (unknown), Hirotake Tokuyama, Kazuki Kobayashi, Koutaro Yokote	15
19	A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammation 2016 ·Scientific Reports ·Ryoichi Ishibashi, Minoru Takemoto, Yoshihiro Akimoto, Takahiro Ishikawa, Peng He, Yoshiro Maezawa, Kenichi Sakamoto, Yuya Tsurutani, Shintaro Ide, Kana Ide, Harukiyo Kawamura, Kazuki Kobayashi, Hirotake Tokuyama, Karl Tryggvason, Christer Betsholtz, Koutaro Yokote	20
20	The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study 2012 ·BioFactors ·(unknown), Minoru Takemoto, Shunichiro Onishi, Ryoichi Ishibashi, Takahiro Ishikawa, (unknown), Masaki Fujimoto, Emiko Okabe, Peng He, Kazuki Kobayashi, Koutaro Yokote	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact